Beta Drugs Limited

BETANotably above fair value

A 6-pillar fundamental profile. Each pillar scored 0–10.

6.5/10 composite

Pulse

— · Neutral

Pulse data unavailable; neutral placeholder

Pulse tracks recent momentum in price, analyst revisions, and news sentiment. Higher means more positive near-term tailwinds.

Quality

5.8 · Moderate

Piotroski 5/9, ROCE 19.1%

Quality captures profitability, return on capital, and earnings consistency. Higher means a better business.

Moat

7.0 · Moderate

Moderate moat

Moat estimates durable competitive advantages — brand, scale, switching costs. Higher means more defensible.

Safety

7.2 · Moderate

D/E 0.60, Int cov 9.5x

Safety looks at balance-sheet quality, leverage, and cash generation. Higher means lower financial risk.

Growth

8.5 · Strong

Rev CAGR 19.2%, EPS CAGR 19.6%

Growth reflects revenue and earnings expansion over recent years. Higher means faster compounding.

Value

— · Insufficient peer data

Only 0 MoS peers in cohort

Value measures how the stock's price compares to its intrinsic worth. Higher means more discount to fair value.

Compare with another stock

Overlay BETA's prism against a peer.

Share this prism

Share on X WhatsApp

Get the full analysis

Interactive DCF, sensitivity, peer comparison, and AI summary for BETA.

Full analysis →

Model estimate. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.